Background subtraction in technetium-99m-MAG3 renography

Journal of Nuclear Medicine

Volumn 38, Issue 1, 1997, Pages 74-79

  Taylor Jr , Andrew ^a   Thakore, Killol ^b   Folks, Russell ^b   Halkar, Raghuveer ^b   Manatunga, Amita ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

background correction; regions of interest; relative renal function

Indexed keywords

MERTIATIDE TC 99M;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; IONIZING RADIATION; KIDNEY FUNCTION; MALE; NEPHRECTOMY; PHANTOM; PRIORITY JOURNAL; PROTEIN BINDING; RENOGRAPHY;

ADULT; AGED; FEMALE; HUMANS; KIDNEY; MALE; MIDDLE AGED; NEPHRECTOMY; OBSERVER VARIATION; RADIOISOTOPE RENOGRAPHY; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M MERTIATIDE;

EID: 1842328061     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Taylor A Jr, Nallly JV. Clinical applications of renal scintigraphy. Am J Roentgenol 1995;164:31-41.
2. Blaufox MD. Procedures of choice in renal nuclear medicine. J Nucl Med 1991;32: 1301-1309.
3. Russell CD, Young D, Billingsley JD, Dubovsky EV. Technical procedures for use of the new kidney agent technetium-99m-MAG3. J Nucl Med Technol 1992; 19:147-152.
4. 99mTc-DTPA (stannous). Am J Roentgenol 1982;138:565-570.
5. Schlegel JU, Halkiopoulos HL, Prima R. Determination of filtration fraction using the gamma scintillation camera. J Urol 1979;14:417-420.
6. 99mTc-MAG3 clearance. J Nucl Med 1995;36:1689-1695.
7. Fine EJ, Axelrod M, Gorkin J, et al. Measurement of effective renal plasma flow: comparison of methods. J Nucl Med 1987;28:1393-1400.
8. Decostre P, Salmon Y Ham HR, Piepsz A. Procedures of choice in nuclear medicine [Letter]. J Nucl Med 1992;33:175.
9. Blaufox MD. Procedures of choice in nuclear medicine [Letter]. J Nucl Med 1992;33:175-176.
10. Piepsz A, Dobbeleir A, Ham HR. Effect of background correction on separate technetium-99m-DTPA renal clearance. J Nucl Med 1990;31:430-435.
11. 99mTc-DTPA. Clin Nucl Med 1994;19:1049-1054.
12. 99mTc-MAG3 clearance. J Nucl Med 1992;33:1620-1622.
13. Russell CD, Taylor A, Eshima D. Estimation of technetium-99m-MAG3 plasma clearance in adults from one of two blood samples. J Nucl Med 1989;30:1955-1959.
14. 99mTc-DTPA renography: comparison of various regions of interest. Clin Phys 1992;12:453-461.
15. Neter J, Wasserman W, Kutner M. Applied linear statistical models, 3rd ed. Homewood, IL: Irwin Publishing Company; 1990.
16. Russell CD, Li L, Kahraman HN, Dubovsky EV. Renal clearances of technetium-99m-MAG3: normal values [Letter]. J Nucl Med 1995;36:706-708.
17. Tondeur M, Piepsz A, Dobbeleir A, Ham H. Technetium-99m-mercaptoacetyltriglycine gamma camera clearance calculations: methodological problems. Eur J Nucl Med 1991;18:83-86.
18. Granerus G, Moonen M. Effects of extra-renal background subtraction and kidney depth correction in the measurement of GFR by gamma camera renography. Nucl Med Commun 1991;12:519-527.
19. 99mTc-DTPA renogram. Radiology 1984;151:627-633.
20. 99mTc-DTPA and the gamma camera: a comparison of methods. Eur J Nucl Med 1985;10:519-521.
21. 99mTc-DTPA renography. Nucl Med Commun 1988;9: 973-985.
22. 99mTc-DTPA renography evaluated by the impact of its components on individual kidney glomerular filtration rate. Nucl Med Commun 1988;9:545-552.
23. 99mTc renal tubular function agent. Semin Nucl Med 1992;22:61-73.
24. Taylor, A, Nally J, Aurell M, et al. Consensus report on ACE inhibitor renography for the detection of renovascular hypertension. J Nucl Med 1996;37:1876-1882.
25. Blaufox MD, Dubovsky EV, Hilson AJW, Taylor A Jr, de Zeeuw R. Report of the working party group on determining the radionuclide of choice. Am J Hypertens 1991;4:747S-748S.